Welcome to the forefront of conversational AI as we explore the fascinating world of AI chatbots in our dedicated blog series. Discover the latest advancements, applications, and strategies that propel the evolution of chatbot technology. From enhancing customer interactions to streamlining business processes, these articles delve into the innovative ways artificial intelligence is shaping the landscape of automated conversational agents. Whether you’re a business owner, developer, or simply intrigued by the future of interactive technology, join us on this journey to unravel the transformative power and endless possibilities of AI chatbots.
Complete your personal information for a more tailored experience
Home
NEW: The STAT Mini
Take a break from the news and try our new weekly crossword.
By Mario Aguilar
Nov. 5, 2025
Health Tech Correspondent
Mario Aguilar
Mario Aguilar covers technology in health care, including artificial intelligence, virtual reality, wearable devices, telehealth, and digital therapeutics. His stories explore how tech is changing the practice of health care and the business and policy challenges to realizing tech’s promise. He’s also the co-author of the free, twice weekly STAT Health Tech newsletter. You can reach Mario on Signal at mariojoze.13.
A Food and Drug Administration advisory committee will meet Thursday to explore a topic that’s been taboo during the Trump administration: Regulating artificial intelligence.
The FDA’s Digital Health Advisory Committee (DHAC) will convene to discuss nitty gritty details around the regulation of therapy chatbots and other mental health devices that use generative AI. The meeting is part of the agency’s ongoing effort to clarify how regulation applies to medical devices based on newer forms of AI, including large language models that produce conversation-like outputs that are not predictable and may misguide users or lead to patient harm.
Advertisement
The DHAC will spend much of the meeting hearing public commentary as well as discussing different scenarios relating to a hypothetical “therapy device” built on a large language model with “with unique outputs that mimic a conversation with a human therapist.” The committee will be asked to consider the device for both prescription and over-the-counter contexts; for adults as well as adolescents; and with indications for major depressive disorder and for multiple mental health conditions. The feedback generated from the meeting will help inform the agency’s work on AI.
STAT+ Exclusive Story
Already have an account? Log in
Already have an account? Log in
Monthly
$39
Totals $468 per year
Totals $468 per year
Starter
$30
for 3 months, then $399/year
Then $399/year
Annual
$399
Save 15%
Save 15%
11+ Users
Custom
Savings start at 25%!
Savings start at 25%!
2-10 Users
$300
Annually per user
$300 Annually per user
To read the rest of this story subscribe to STAT+.
Mario Aguilar
Health Tech Correspondent
Mario Aguilar covers technology in health care, including artificial intelligence, virtual reality, wearable devices, telehealth, and digital therapeutics. His stories explore how tech is changing the practice of health care and the business and policy challenges to realizing tech’s promise. He’s also the co-author of the free, twice weekly STAT Health Tech newsletter. You can reach Mario on Signal at mariojoze.13.
Tech is transforming health care and life sciences. Our original reporting is here to keep you ahead of the curve.
Your data will be processed in accordance with our Privacy Policy and Terms of Service. You may opt out of receiving STAT communications at any time.
Alex Hogan
Advertisement
Allison DeAngelis and Jason Mast
By Jason Mast
By Lizzy Lawrence and Adam Feuerstein
By O. Rose Broderick and Lev Facher
By Andrew Joseph
Share options
X
Bluesky
LinkedIn
Facebook
Doximity
Copy link
Reprints
A decade of reporting from the frontiers of health and medicine
Company
Account
More